MESS-study MRSA Eradication Study Skåne

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2013 by Region Skane
Information provided by (Responsible Party):
Region Skane Identifier:
First received: January 3, 2011
Last updated: July 5, 2013
Last verified: June 2013

The purpose of this study is to determine whether systemic antibiotic treatment with rifampicin and clindamycine or trimethoprim-sulfa in addition to topical treatment with mupirocin is more effective than only topical treatment to eradicate MRSA in throatcarriers

Condition Intervention
Throatcarriers of MRSA
Drug: Mupirocin
Drug: Rifampin+Clindamycine or Trimehoprimsulfa

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: MESS- MRSA Eradication Study Skåne. A Comparison Between Systemic Antibiotic Treatment in Combination With Topical Mupirocintreatment With Only Topical Mupiroicintreatment to Eradicate MRSA in Throat Carriers

Resource links provided by NLM:

Further study details as provided by Region Skane:

Primary Outcome Measures:
  • Culture for MRSA [ Time Frame: after 6 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 230
Study Start Date: March 2011
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Mupirocin
Topical treatment
Drug: Mupirocin
Topical in the nose 3 times daily for 5 days
Drug: Rifampin+Clindamycine or Trimehoprimsulfa
Rifampicin 10 mg/kgx1xVII Clindamycine 300 mgx3 Trimethoprimsulfa 400mg/80mg 2x2
Active Comparator: Rifampicin+Clindamycine or Trimethoprimsulfa
Rifampicin 10 mg/kgx1xVII Clindamycine 300 mgx3xVII Trimethoprimsulfa 400mg/80mg 2x2
Drug: Rifampin+Clindamycine or Trimehoprimsulfa
Rifampicin 10 mg/kgx1xVII Clindamycine 300 mgx3 Trimethoprimsulfa 400mg/80mg 2x2


Ages Eligible for Study:   5 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Colonized with MRSA in the throat Older than 5 years MRSA-bacteria sensitive for Rifampicin and Clindamycine or Trimethoprimsulfa -

Exclusion Criteria:

Allergy to the studymedication Healthcareworkers Pregnancy Active infection with MRSA Immunosuppression Treatment with other antibiotic during the studyperiod

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01269541

Contact: Eva Melander, MD Phd +4640-33 74 86
Contact: Anna-Karin Larsson, MD +464062950

Helsingborg hospital Recruiting
Helsingborg, Skåne, Sweden
Contact: Anna-Karin Larsson, MD   
Principal Investigator: Anna-Karin Larsson, MD         
Kristianstad hospital Recruiting
Kristianstad, Skåne, Sweden
Contact: Henrik Elmrud, MD   
Principal Investigator: Henrik Elmrud, MD         
Infectious department SUS Lund Recruiting
Lund, Skåne, Sweden
Contact: Per Åkesson, MD Phd   
Principal Investigator: Per Åkesson, MD Phd         
SUS Malmö Recruiting
Malmö, Skåne, Sweden
Contact: Anna Nilsson, MD PhD   
Principal Investigator: Anna Nilsson, MD, PhD         
Karolinska university hospital Active, not recruiting
Stockholm, Sweden
Örebro university hospital Active, not recruiting
Örebro, Sweden
Sponsors and Collaborators
Region Skane
Principal Investigator: Eva Melander, MD PHD Labmedicin Skåne Malmö
  More Information

No publications provided

Responsible Party: Region Skane Identifier: NCT01269541     History of Changes
Other Study ID Numbers: MRSA-2010, 2010-019727-55
Study First Received: January 3, 2011
Last Updated: July 5, 2013
Health Authority: sweden: Läkemedelsverket (Medical products agency) processed this record on March 30, 2015